作者
Olivia Almendares, Jessica L Prince-Guerra, Leisha D Nolen, Jayleen KL Gunn, Ariella P Dale, Sean A Buono, Molly Deutsch-Feldman, Suganthi Suppiah, LiJuan Hao, Yan Zeng, Valerie A Stevens, Kristen Knipe, Justine Pompey, Christine Atherstone, David P Bui, Tracy Powell, Azaibi Tamin, Jennifer L Harcourt, Marla Petway, Caitlin Bohannon, Jennifer M Folster, Adam MacNeil, Reynolds Salerno, Wendi Kuhnert-Tallman, Jacqueline E Tate, Natalie Thornburg, Hannah L Kirking, Khalilullah Sheiban, Julie Kudrna, Theresa Cullen, Kenneth K Komatsu, Julie M Villanueva, Dale A Rose, John C Neatherlin, Mark Anderson, Paul A Rota, Margaret A Honein, William A Bower, CDC COVID-19 Surge Diagnostic Testing Laboratory Patricia L. Shewmaker CDC, Magdalena Medrzycki CDC, Phili Wong CDC, Shilpi Jain CDC, Alexandra Tejada-Strop CDC, Shannon Rogers CDC, Brian Emery CDC, Houping Wang CDC
发表日期
2022/1/19
期刊
Journal of Clinical Microbiology
卷号
60
期号
1
页码范围
e01742-21
出版商
American Society for Microbiology
简介
Point-of-care antigen tests are an important tool for SARS-CoV-2 detection. Antigen tests are less sensitive than real-time reverse transcriptase PCR (rRT-PCR). Data on the performance of the BinaxNOW antigen test compared to rRT-PCR and viral culture by symptom and known exposure status, timing during disease, or exposure period and demographic variables are limited. During 3 to 17 November 2020, we collected paired upper respiratory swab specimens to test for SARS-CoV-2 by rRT-PCR and Abbott BinaxNOW antigen test at two community testing sites in Pima County, Arizona. We administered a questionnaire to capture symptoms, known exposure status, and previous SARS-CoV-2 test results. Specimens positive by either test were analyzed by viral culture. Previously we showed overall BinaxNOW sensitivity was 52.5%. Here, we showed BinaxNOW sensitivity increased to 65.7% among currently …
引用总数
20212022202320242982